-
Zhongying Biologics Standard-grade Reagents were unveiled, and the application of NK cell tumor therapy received attention from the industry
Time of Update: 2022-10-02
Zhongying Bio showcases NK cell clinical technology achievements and leading the industry in advantageous technology Zhongying Bio's drug standard grade NK/CAR-NK cell amplification reagent will be displayed during the conference, Zhongying Bio has independent intellectual property rights based on IL21 trophoblast cell preparation NK cell method relative to other ways to be stable, the prepared final product effector cells can basically reach more than 90% purity, and the expansion multiple is high, the killing function is strong.
-
Organized by the SPACE Enterprise Research Institute of the University of Hong Kong
Time of Update: 2022-10-02
AI+digital health reconstructs the boundaries of the healthcare industry In August 2022, the SPACE Enterprise Research Institute of the University of Hong Kong held two special lectures on "Digital H
-
【CDE Acceptance Fact Sheet】An overview of CDE acceptance from September 12 to September 18
Time of Update: 2022-10-02
The status of acceptance of the consistency evaluation is as follows: There are 29 acceptance numbers for Class 1 drugs, including 23 chemical drugs and 6 therapeutic biological products.
-
Leading the development and innovation of the blood oxygen industry: Interview with Mr. Qian Xiaolun, Vice Chairman and General Manager of Chaosi
Time of Update: 2022-10-02
Beijing Chaosi with Internet medical, respiratory, cardiovascular, sleep and other comprehensive products and solutions unveiled MFC 2022, the company is affiliated to Hongri Pharmaceutical, is a collection of research and development, manufacturing and sales of medical, household health medical products as one of the high-tech enterprises, is one of the largest manufacturers of medical monitoring and household electronic medical products in China.
-
Advance Media's interim results: Strong growth of the business twin engines, strong marketing system to promote the full commercialization
Time of Update: 2022-10-02
Key Operating Summary: Despite the impact of the epidemic in the first half of the year, sales of transcatheter valve therapy business and neurointervention business were strong, with revenue of RMB52.
-
Time of Update: 2022-10-02
DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions.
DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions.
DFE Pharma is a global leader in pharmaceutical and nutraceutical excipient solutions.
-
This 10 billion market will be impacted by a large number of blockbuster new drugs!
Time of Update: 2022-10-02
In the national collection, many varieties of drugs for the treatment of diseases related to gastric acid secretion have been won by domestic enterprises, such as in the aluminum magnesium carbonate market, in 2021, Chongqing Huasen Pharmaceutical won the bid, and Pfizer lost its qualifications; In the esomeprazole market, the original research AstraZeneca has not entered the collection, which has affected the continuous decline in market share.
-
Analysis of the current situation and competitive landscape of the oral drug market
Time of Update: 2022-10-02
Dentistry belongs to the Department of Stomatology, in the PDB database, dental drugs do not have a separate treatment sub-category, so this paper analyzes the sales amount and changes of dental drugs, mainly and several key drugs used in dentistry in sample hospitals, average unit price, etc.
-
Artificial intelligence assists in the research and development of super antibacterial drugs, and the cost is reduced by 70%!
Time of Update: 2022-10-02
There is a "double ten law" in the pharmaceutical industry, that is, the average cost of a new drug from research and development to the market is more than 1 billion US dollars, and the research and
-
Pfizer sold the factory, Suqiao was acquired, Kewang "optimized production capacity", and the self-built factory building was "not fragrant"?
Time of Update: 2022-10-02
Earlier, WuXi Biologics CEO Chen Zhisheng once said: "Some companies have built factories that exceed their own needs or capabilities, and now there is a 'factory building tide' in China, what will be the situation in five years?" ” China's biomedical industry is developing rapidly, and in recent years, many enterprises have increased their efforts to build their own factories and expand production capacity.
-
Li Yan, president of Qilu Pharmaceutical Group, accompanied Lu Lin and his party to visit the enterprise
Time of Update: 2022-10-02
Li Yan, President of Qilu Pharmaceutical Group, expressed a warm welcome to the arrival of Lu Lin and his party, accompanied by Lu Lin and his party, Lu Lin and his party visited the exhibition hall of Qilu Pharmaceutical Enterprise, CMC R&D platform and intelligent manufacturing production workshop, and deeply and comprehensively understood the development process, industrial layout, corporate culture construction, drug research and development of the enterprise.
-
In September, a large number of medical consumables ushered in a wave of price cuts
Time of Update: 2022-10-02
According to the "Announcement", the scope of the simulation declaration of the purchase of this volume includes ultrasonic knife heads, intraocular lenses, and enterprises participating in the declaration of this procurement of the amount of the belt should strictly follow the national provincial platform minimum purchase of the selected registration certificate or single product specifications and models to declare the products participating in the procurement of the quantity.
-
Gu Yitang was approved by the Ministry of Education for the 2022 "Industry-University Cooperation and Collaborative Education" project
Time of Update: 2022-10-02
Red Net Moment News September 2 (Correspondent Yuan Wenbin) On August 26, 2022, the Ministry of Education announced the industry-academia cooperation collaborative education project guide through the
-
Kangtai Biotech won the "2021 China Biomedical Enterprises Top 10"
Time of Update: 2022-10-02
On July 12, the Expert Committee of China's Top 100 Pharmaceutical Industry released the "2021 China Pharmaceutical Industry Top 100 Series List". Shenzhen Kangtai Biological Products Co. , Ltd. (sto
-
Pharmaceutical companies have joined hands to jointly research new drugs, and the results are constantly emerging
Time of Update: 2022-10-02
Recently, the European Medicines Agency (EMA) Committee on Medicinal Products for Human Use (CHMP) recommended the approval of Beyfortus, jointly developed by Sanofi and AstraZeneca, for use in newborns and infants to help prevent RSV lower respiratory tract infections as the first respiratory syncytial virus (RSV) season arrives.
-
Notice on the Special Activities of Healthy China Action on Health Promotion of Traditional Chinese Medicine
Time of Update: 2022-10-02
Provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps Health China Action Promotion Office, Health Commission, and Bureau
-
The price of medicinal herbs has risen again? The reasons are complex and diverse
Time of Update: 2022-10-02
In addition to objective factors, artificial hoarding speculation is also an important influencing factor for the price increase of medicinal materials, especially the main catalyst for the price increase of rigid Chinese herbal medicine categories.
-
Semi-annual report observation: the performance of pharmaceutical machinery enterprises in the first half of the year increased, but the number of institutional positions decreased
Time of Update: 2022-10-02
At present, listed pharmaceutical equipment companies have basically disclosed their 2022 semi-annual reports, and overall, most of the company's performance has achieved growth. However, the author n
-
Ovarian cancer targeted drug Nirapali Chinese patients first-line whole population maintenance therapy research data released!
Time of Update: 2022-10-02
Studies have confirmed that the ovarian cancer targeting drug Nirapalil has outstanding overall results in the Chinese population The PRIME study showed that first-line maintenance therapy with the ovarian cancer target drug Nirapalil had a statistically and clinically significant benefit in improving PFS in the entire population compared with placebo, with median progression-free survival of 24.
-
The prosperity of pharmaceutical and other industries is good, and the performance of many pharmaceutical companies in the first three quarters is pre-gratifying
Time of Update: 2022-10-02
0985 million yuan; Kaipu Bio expects net profit in the first three quarters to increase by 108.
0985 million yuan; Kaipu Bio expects net profit in the first three quarters to increase by 108.
